Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.019 | 0.7 |
mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.058 | 0.7 |
mRNA | Pazopanib | FIMM | pan-cancer | AAC | 0.061 | 0.7 |
mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.7 |
mRNA | Bicalutamide | FIMM | pan-cancer | AAC | 0.055 | 0.7 |
mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |